Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT04588025 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2026-02-27
Summary
The goal of this study is to investigate whether the therapeutic response of pancreatic tumors can be accurately assessed using quantitative DCE-MRI, when the inter/intra-scanner variability is reduced using the Point-of-care Portable Perfusion Phantom, P4. The intra-scanner variability over time leads to errors in therapy monitoring, while the inter-scanner variability impedes the comparison of data among institutes. The P4 is small enough to be imaged concurrently in the bore of a standard MRI scanner with a patient for real-time quality assurance. The P4 is safe, inexpensive and easily operable, thus it has great potential for widespread and routine clinical use for accurate diagnosis, prognosis and therapy monitoring.
This study has identified two arms, one arm is healthy individuals that will undergo DCE MRI at three different MRI locations to establish baseline results. The healthy volunteers will undergo these MRIs prior to the second arm, which contains patients with pancreatic cancer. The pancreatic cancer patients will only have DCE MRI done at one location.
Conditions
Interventions
- DEVICE
-
Point-of-care Portable Perfusion Phantom, P4
P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Sponsors & Collaborators
-
Ohio State University
lead OTHER
Principal Investigators
-
Harrison Kim, PhD · Ohio State University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-14
- Primary Completion
- 2026-10-31
- Completion
- 2027-10-31
Countries
- United States
Study Locations
More Related Trials
-
Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma
NCT02775786 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
NCT05340569 ·Status: COMPLETED ·Phase: NA
-
Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
NCT02245217 ·Status: COMPLETED ·Phase: NA
-
An Investigational Scan (MR DENSE) in Detecting Early Chemotherapy-Related Liver Injury Before Surgery in Patients With Resectable Colorectal Liver Metastases
NCT05059717 ·Status: WITHDRAWN ·Phase: NA
-
Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer
NCT02550847 ·Status: UNKNOWN
-
Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma
NCT02028377 ·Status: COMPLETED ·Phase: NA
-
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
NCT05558904 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
NCT03145077 ·Status: RECRUITING ·Phase: NA
-
68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma
NCT05275985 ·Status: UNKNOWN ·Phase: NA
-
A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma
NCT06277206 ·Status: COMPLETED
-
Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer
NCT03469726 ·Status: UNKNOWN ·Phase: NA
-
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
NCT06842303 ·Status: RECRUITING ·Phase: NA
-
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
NCT05957250 ·Status: RECRUITING ·Phase: NA
-
18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas
NCT01485679 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT04700488 ·Status: SUSPENDED ·Phase: NA
-
Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.
NCT03202199 ·Status: UNKNOWN ·Phase: NA
-
Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4)
NCT00222885 ·Status: COMPLETED
-
The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.
NCT02777463 ·Status: COMPLETED
-
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
NCT02995902 ·Status: COMPLETED ·Phase: NA
-
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117 ·Status: TERMINATED
-
Magnetic Resonance Imaging (MRI) in Motion
NCT02019199 ·Status: COMPLETED
-
Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
NCT00527891 ·Status: COMPLETED
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus
NCT00222781 ·Status: COMPLETED
-
4D-MRI for Precision Medicine
NCT04657042 ·Status: RECRUITING